Jump to Main Content

FDA Alerts

FDA Approves L-glutamine Powder for the Treatment of Sickle Cell Disease

The U.S. Food and Drug Administration approved L-glutamine oral powder (Endari™, Emmaus Medical, Inc.) for oral administration to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older.
Citations